Cucurbitacin B

Name: Cucurbitacin B
Brand: MedChemExpress
SKU: HY-N0416
Rating: 5.0 (11 reviews)

Cat. No.: HY-N0416 Purity: 99.81%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity.

For research use only. We do not sell to patients.

CAS No. : 6199-67-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of Cucurbitacin B:

11 Publications Citing Use of MCE Cucurbitacin B

Cell Proliferation/Viability Assay

Cell Imaging/Staining

Flow Cytometry

RT-PCR

: Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 28;25(17):9333. [Abstract]; Effect of Cucurbitacin B (Cu B) on the cell viability of WPMY-1 and HPRF. Cu B and Doxa inhibited the proliferation of WPMY-1 and HPRF cells based on CCK-8 results. Prostate cells were treated with vehicle (0.1% DMSO), doxazosin (40 μM), or Cu B (12.5 nM, 25 nM, 50 nM, 100 nM, 200 nM) for 48 h and 72 h. The positive control drug doxazosin 40 μM significantly reduced the survival rate of both cells compared with the solvent control group. After 72 h of treatment with Cu B at medium to high concentrations (25 nM–200 nM), the survival rate of WPMY-1 cells was significantly reduced compared with the solvent control group. Only after 72 h of treatment with the highest concentration (200 nM) of Cu B was the survival rate of HPRF cells significantly reduced compared with the solvent control group.

: Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 28;25(17):9333. [Abstract]; Apoptosis of WPMY-1 and HPRF that were treated with Cucurbitacin B (Cu B) and Doxa. Cu B and Doxa induced the apoptosis of prostate cells based on the results of flow cytometry analysis. In WPMY-1 cells, the apoptosis rate of the Doxa group and the middle-to-high concentration Cu B (50 nM–100 nM; 48 h) group was significantly increased compared with the control group. In HPRF cells, only the apoptosis rate of the high-concentration Cu B (50 nM–100 nM; 48 h) group was significantly increased compared with the control group.

: Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]; H₂O₂-treated NIH3T3 cells were incubated in complete medium with different STAT3 inhibitors including AG490 (50 μM), Stattic (0.5 μM), Cucurbitacin B (CuB, 40 ng/mL), S3I-201 (50 μM) and NF-κB inhibitor QNZ (5 μM) for 3 days. Cells lysates were subjected to immunoblotting. The results showed that Cucurbitacin B reduced the expression of p21.

: Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]; H₂O₂-treated NIH3T3 cells were incubated in complete medium with different STAT3 inhibitors including AG490 (50 μM), Stattic (0.5 μM), Cucurbitacin B (CuB, 40 ng/mL), S3I-201 (50 μM) and NF-κB inhibitor QNZ (5 μM) for 3 days. Cells were stained for SA-β-Gal and quantified.

: Cucurbitacin B purchased from MedChemExpress. Usage Cited in: Mech Ageing Dev. 2020 Oct;191:111347. [Abstract]; H₂O₂-treated NIH3T3 cells were incubated in complete medium with different STAT3 inhibitors including AG490 (50 μM), Stattic (0.5 μM), Cucurbitacin B (CuB, 40 ng/mL), S3I-201 (50 μM) and NF-κB inhibitor QNZ (5 μM) for 3 days. qRT-PCR analyses of SASP factors expression.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Isoforms

HIF-1α HIF

View All Integrin Isoform Specific Products:

View All Isoforms

αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.088 μM Compound: CuB; 1	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
BXPC-3	IC₅₀	0.022 μM Compound: CuB; 1	Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
CFPAC-1	IC₅₀	0.023 μM Compound: CuB; 1	Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
CHO	IC₅₀	1.99 μM Compound: 2	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 30108825]
HCT-116	IC₅₀	0.019 μM Compound: CuB; 1	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
HeLa	IC₅₀	0.024 μM Compound: CuB; 1	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
HepG2	IC₅₀	0.051 μM Compound: CuB; 1	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
Huh-7	IC₅₀	4.1 μM Compound: 6; CuB	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38382391]
L02	IC₅₀	0.011 μM Compound: CuB; 1	Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
LNCaP	IC₅₀	0.1 μM Compound: 18	Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability by CellTitre-Glo assay Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability by CellTitre-Glo assay	[PMID: 37428122]
LNCaP	IC₅₀	0.1 μM Compound: 8	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 30195238]
MCF7	IC₅₀	0.04 μM Compound: CuB; 1	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
MCF7	IC₅₀	12 μM Compound: CuB	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]
MCF7	IC₅₀	9.72 μM Compound: CuB	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay	[PMID: 31620225]
MDA-MB-231	IC₅₀	0.037 μM Compound: CuB; 1	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
PANC-1	IC₅₀	0.067 μM Compound: CuB; 1	Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
PC-3	IC₅₀	0.1 μM Compound: 8	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 30195238]
SK-OV-3	IC₅₀	0.047 μM Compound: CuB; 1	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 37681508]
Vero	IC₅₀	0.04 μM Compound: CuB	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]

In Vitro

Cucurbitacin B (up to 40 μM, 12-48 h) inhibits the cell growth and arrests cell cycle progression at the G2/M phase in CCA cell lines ^[2].
Cucurbitacin B (0.1, 0.3 and 1 μM) increases the level of total superoxide dismutase(T-SOD) and SOD-1, but decrease the reactive oxygen species (ROS) and malondialdehyde (MDA) in BY4741 yeast cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	CCA cell lines
Concentration:	0.1, 1 0.5, 1,5, 10, 20, 40 μM
Incubation Time:	24 and 48 h
Result:	Decreased cell viability in a dose-dependent and time-dependent manner with the IC₅₀ values of 13:44 μM for 24 h and 1.55 for 48 h.

Cell Cycle Analysis^[2]

Cell Line:	CCA cell lines
Concentration:	0.1, 1, 10 μM
Incubation Time:	24 h
Result:	Arrested cell cycle progression at the G2/M phase.

Western Blot Analysis^[2]

Cell Line:	CCA cell lines
Concentration:	0.1, 1 0.5, 1,5, 10, 20, 40 μM
Incubation Time:	12 and 24 h
Result:	Decreased the expression of Cyclin A, Cyclin D1, Cdc25A, but increased the level of p21.

In Vivo

Cucurbitacin B (5 mg/kg, oral administration 10day) B shows protective effects against carrageenan-induced prostatitis in rats^[4].
Cucurbitacin B (20-50 mg/kg for i.p., 28 day) B afford a decline in AD symptoms and protects neurons against STZ-ICV toxicity that improved memory functions in rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Carrageenan-induced prostatic inflammation in rats^[4]
Dosage:	5mg/kg/day for 10day
Administration:	Oral administration
Result:	Decreased the level of TNF-α, IL-1b, COX-2 and iNOS in prostatic tissues.

Animal Model:	STZ-ICV rat prototype of AD-like dementia^[5]
Dosage:	20, 50mg/kg/day for 28days
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased the TNF-α, IL-1β, MPO, iNOS, acetylcholinesterase, and glutamate levels, but increased gamma-aminobutyric acid. Increase in viable neuron density in the cortex and hippocampus of rats.

Molecular Weight

558.70

Formula

C₃₂H₄₆O₈

CAS No.

6199-67-3

Appearance

Solid

Color

White to off-white

SMILES

O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C([C@@H](O)C[C@@]4([H])[C@]3(C)C2=O)=O

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (178.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7899 mL	8.9493 mL	17.8987 mL
5 mM	0.3580 mL	1.7899 mL	3.5797 mL
10 mM	0.1790 mL	0.8949 mL	1.7899 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.81%

Select Batch:

Data Sheet (283 KB) SDS (419 KB)

COA (252 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Dai S, , et al. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics. Pharmacol Res. 2023;187:106587. [Content Brief]

[2]. Klungsaeng, et al. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. Am J Chin Med. 2020;48(6):1475-1489. [Content Brief]

[3]. Lin Y, et al. Cucurbitacin B Exerts Antiaging Effects in Yeast by Regulating Autophagy and Oxidative Stress. Oxid Med Cell Longev. 2019;2019:4517091. [Content Brief]

[4]. Aljohani OS. Phytochemical evaluation of Cucumis prophetarum: protective effects against carrageenan-induced prostatitis in rats. Drug Chem Toxicol. 2022;45(4):1461-1469. [Content Brief]

[5]. Liu Z, Kumar M, Kabra A. Cucurbitacin B exerts neuroprotection in a murine Alzheimer's disease model by modulating oxidative stress, inflammation, and neurotransmitter levels. Front Biosci (Landmark Ed). 2022;27(2):71. [Content Brief]

[6]. Shang Y, et al. Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN. Eur Rev Med Pharmacol Sci. 2014;18(21):3297-303. [Content Brief]

[7]. Zhang M, et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep. 2014 Dec;10(6):2905-11. [Content Brief]

[8]. Guo J, et al. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. PLoS One. 2014 Feb 4;9(2):e88140. [Content Brief]

[9]. Gupta P, et al. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget. 2014 Apr 15;5(7):1812-28. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7899 mL	8.9493 mL	17.8987 mL	44.7467 mL
	5 mM	0.3580 mL	1.7899 mL	3.5797 mL	8.9493 mL
	10 mM	0.1790 mL	0.8949 mL	1.7899 mL	4.4747 mL
	15 mM	0.1193 mL	0.5966 mL	1.1932 mL	2.9831 mL
	20 mM	0.0895 mL	0.4475 mL	0.8949 mL	2.2373 mL
	25 mM	0.0716 mL	0.3580 mL	0.7159 mL	1.7899 mL
	30 mM	0.0597 mL	0.2983 mL	0.5966 mL	1.4916 mL
	40 mM	0.0447 mL	0.2237 mL	0.4475 mL	1.1187 mL
	50 mM	0.0358 mL	0.1790 mL	0.3580 mL	0.8949 mL
	60 mM	0.0298 mL	0.1492 mL	0.2983 mL	0.7458 mL
	80 mM	0.0224 mL	0.1119 mL	0.2237 mL	0.5593 mL
	100 mM	0.0179 mL	0.0895 mL	0.1790 mL	0.4475 mL

Cucurbitacin B Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Cucurbitacin B

Customer Review

Other Forms of Cucurbitacin B:

11 Publications Citing Use of MCE Cucurbitacin B

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Integrin Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

View All COX Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cucurbitacin B Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cucurbitacin B

Customer Review

Other Forms of Cucurbitacin B:

Cucurbitacin B Related Antibodies

11 Publications Citing Use of MCE Cucurbitacin B

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Integrin Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

View All COX Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Cucurbitacin B Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cucurbitacin B Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report